Physician profile
Anne E Mosiman
NPI 1861509168
$7,204.47
in general payments reported to CMS, 2019-2025
26 companies · $942 in 2025
The $942 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,397 · 2022: $1,214 · 2023: $1,294 · 2024: $1,358 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,521 · Education: $72.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,521.43 |
| Education | $72.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,756.73 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,625.74 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Astrazeneca Pharmaceuticals LP | $514.54 | 2021-2025 | Farxiga, Airsupra |
| Amarin Pharma, INC. | $371.96 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $332.15 | 2021-2025 | Belsomra, Steglatro, Steglujan |
| Dexcom, INC. | $314.77 | 2021-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $298.24 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Corcept Therapeutics | $289.90 | 2021-2023 | Korlym |
| Abbvie INC. | $269.70 | 2021-2024 | |
| Esperion Therapeutics, INC. | $238.66 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $174.44 | 2021-2023 | |
| Amgen INC. | $162.19 | 2021-2025 | Evenity, Krystexxa |
| Biohaven Pharmaceuticals, INC. | $141.22 | 2021 | |
| Si-Bone, INC. | $130.73 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.08 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $113.89 | 2021-2022 | |
| Exact Sciences Corporation | $54.37 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $53.61 | 2022-2023 | Trintellix |
| Abbott Laboratories | $52.69 | 2021-2023 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $41.97 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $39.76 | 2022 | |
| Pfizer INC. | $29.66 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $24.39 | 2025 | Gemtesa |
| Astellas Pharma US INC | $17.64 | 2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.02 | 2024 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $15.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Mosiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.